Extended lamivudine consolidation therapy in hepatitis B e antigen-positive chronic hepatitis B patients improves sustained hepatitis B e antigen seroconversion

References

• Maynard JE. Hepatitis B: global importance and need for control. Vaccine 1990;8:518–20.
   Google Scholar
• Lok AS, Heathcote EJ, Hoofnagel JH. Management of hepatitis B: 2000–summary of a workshop. Gastroenterology 2001;120:1828–53.
   PubMed Web of Science ®Google Scholar
• Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988;8:493–6.
   PubMed Web of Science ®Google Scholar
• Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22,707 men in Taiwan. Lancet 1981;2:1129–33.
   PubMed Web of Science ®Google Scholar
• Chen DS. From hepatitis to hepatoma: lessons from type B viral hepatitis. Science 1993;262:369–70.
   PubMed Web of Science ®Google Scholar
• Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. Inhibition of the replication of hepatitis B virus in vitro by 2`, 3`-dideoxy-3`-thiacytidine and related analogues. Proc Natl Acad Sci U S A 1991;88:8495–9.
   PubMed Web of Science ®Google Scholar
• Liaw YF, Leung NWY, Chang TT, Guan R, Tai DI, Ng KY, Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000;119:172–80.
   PubMed Web of Science ®Google Scholar
• Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001;33:1527–32.
   PubMed Web of Science ®Google Scholar
• Liaw YF. Current therapeutic trends in therapy for chronic viral hepatitis. J Gastroenterol Hepatol 1997;12:S346–53.
   PubMed Web of Science ®Google Scholar
• Dienstag JL, Schiff ER, Mitchell M, Casey DE Jr, Gitlin N, Lissoos T, Extended lamivudine retreatment for chronic hepatitis: maintenance of viral suppression after discontinuation of therapy. Hepatology 1999;30:1082–7.
   PubMed Web of Science ®Google Scholar
• Dienstag JL, Cianciara J, Karayalcin S, Kowdley KV, Willems B, Plisek S, Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 2003;37:748–55.
   PubMed Web of Science ®Google Scholar
• Lai CL, Chien RN, Leung NWY, Chang TT, Guan R, Tai DI, The Asia Hepatitis Lamivudine Study Group. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998;339:61–8.
   PubMed Web of Science ®Google Scholar
• Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Hepatitis Be. antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000;32:803–6.
   PubMed Web of Science ®Google Scholar
• Lee KM, Cho SW, Kim SW, Kim HJ, Hahm KB, Kim JH. Effect of virological response on post-treatment durability of lamivudine induced HBeAg seroconversion. J Viral Hepat 2002;9:208–12.
   PubMed Web of Science ®Google Scholar
• Lee CM, Ong GY, Lu SN, Wang JH, Liao CA, Tung HD, Durability of lamivudine induced HBeAg seroconversion for chronic hepatitis B patients with acute exacerbation. J Hepatol 2002;37:669–74.
   PubMed Web of Science ®Google Scholar
• Chien RN, Yeh CT, Tsai SL, Chu CM, Liaw YF. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology 2003;38:1267–73.
   PubMed Web of Science ®Google Scholar
• Byun KS, Kwon OS, Kim JH, Yim HJ, Chang YJ, Kim JY, Factors related to post-treatment relapse in chronic hepatitis B patients who lost HBeAg after lamivudine therapy. J Gastroenterol Hepatol 2005;20:1838–42.
   PubMedGoogle Scholar
• Yoon SK, Jang JW, Kim CW, Bae SH, Choi JY, Choi SW, Long-term results of lamivudine monotherapy in Korean patients with HBeAg-positive chronic hepatitis B: response and relapse rates, and factors related to durability of HBeAg seroconversion. Intervirology 2005;48:341–9.
   PubMedGoogle Scholar
• Ryu SH, Chung YH, Choi MH, Kim JA, Shin JW, Jang MK, Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg seroconversion. J Hepatol 2003;39:614–9.
   PubMed Web of Science ®Google Scholar
• Lok SF, McMahon BJ. AASLD practice guidelines: Chronic hepatitis B. Hepatology 2007;45:507–39.
   PubMed Web of Science ®Google Scholar
• Liaw YF, Leung N, Guan R, Lau GK, Merican I, McCaughan G, Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 2005;25:472–89.
   PubMed Web of Science ®Google Scholar
• Hung CH, Lu SN, Wang JH, Lee CM, Chen TM, Tung HD, Correlation between ultrasonographic and pathologic diagnoses of hepatitis B and C virus-related cirrhosis. J Gastroenterol 2003;38:153–7.
   PubMed Web of Science ®Google Scholar
• Chen CH, Eng HL, Lee CM, Kuo FY, Lu SN, Huang CM, Correlations between hepatitis B virus genotype and cirrhotic or non-cirrhotic hepatoma. Hepatogastroenterology 2004;51:552–5.
   PubMedGoogle Scholar
• Lee CM, Chen CH, Lu SN, Tung HD, Chou WJ, Wang JH, Prevalence of clinical implications of hepatitis B virus genotypes in southern Taiwan. Scand J Gastroenterol 2003;1:95–101.
   Google Scholar
• Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995;13:29–60.
   PubMed Web of Science ®Google Scholar
• Davis GL, Hoofnagle JH. Reactivation of chronic hepatitis B infection. Gastroenterology 1987;92:2028–31.
   PubMed Web of Science ®Google Scholar
• Boni C, Penna A, Ogg GS, Bertoletti A, Pilli M, Cavallo C, Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 2001;33:963–71.
   PubMed Web of Science ®Google Scholar
• Boni C, Bertoletti A, Penna A, Cavalli A, Pilli M, Urbani S, Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998;102:968–75.
   PubMed Web of Science ®Google Scholar
• Fourel I, Cullen JM, Saputelli J, Aldrich CE, Schaffer P, Averett DR, Evidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of chronically infected ducks. J Virol 1994;68:8321–30.
   PubMed Web of Science ®Google Scholar
• Mason WS, Cullen J, Moraleda G, Saputelli J, Aldrich CE, Miller DS, Lamivudine therapy of WHV-infected woodchucks. Virology 1998;245:18–32.
   PubMed Web of Science ®Google Scholar
• Chen CH, Lee CM, Lu SN, Wang JH, Tung HD, Hung CH, Comparison of clinical outcome between patients continuing and discontinuing lamivudine therapy after biochemical breakthrough of YMDD mutants. J Hepatol 2004;41:454–61.
   PubMedGoogle Scholar
• Van Nunen AB, Hansen BE, Suh DJ, Lohr HF, Chemello L, Fontaine H, Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut 2003;52:420–4.
   PubMed Web of Science ®Google Scholar
• Chen CH, Lee CM, Lu SN, Changchien CS, Wang JC, Wang JH, Comparison of sequence changes of precore and core promoter regions in HBeAg-positive chronic hepatitis B patients with and without HBeAg clearance in lamivudine therapy. J Hepatol 2006;??:76–82.
   PubMedGoogle Scholar
• Hsu YS, Chien RN, Yeh CT, Sheen IS, Chiou HY, Chu CM, Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002;35:1522–7.
   PubMed Web of Science ®Google Scholar